Korean-based public pharmaceutical company Peptron who focus on peptide engineering and developing sustained-release medicine technology, has developed a novel form of the GLP-1 receptor agonist SR-exenatide that effectively crosses the blood-brain barrier and provides sustained release of the neuroprotective peptide in the brain.

The development of exendin-4 to treat Parkinson's has been limited by the medication's short half-life, or the duration of action of the drug in the body. The synthetic version of exendin-4 is Bydureon® - this drug was recently trialled in people with Parkinson's funded by The Cure Parkinson's Trust. Read more about the promising results of this trial.

Peptron has now released data showing the new sustained-release (SR) exendin-4 formulation reduces degeneration of neurons in animal models of Parkinson's disease. This is another breakthrough in the developing armoury of treatments using GLP-1's as potential drugs to stop, slow or even reverse Parkinson's.  

"We are proud to apply our decades of experience in developing sustained-release therapeutics to the great unmet medical need of millions of people around the world who suffer from Parkinson's disease," said Ho-Il Choi, PhD, Chief Executive Officer and Director of Peptron.

Read the full article here: www.prnewswire.com/news-releases/peptron-announces-published-data-showing-a-new-sustained-release-exendin-4-formulation-prevents-neurodegeneration